Fed's Williams says tariff economic impact is only just starting

Taco Bell is rolling out a fresh lineup of limited-time menu items, pulling some of its experimental test kitchen creations into the real world for fans to try.

Editor’s Note: If you're a Taco Bell fan, this is your chance to taste something new before it's gone. Limited-edition items often drive buzz and foot traffic, so expect lines—and maybe even some social media hype—around these exclusives. For the chain, it's a way to keep the menu exciting and test potential future hits.

Shares of Archer-Daniels-Midland (ADM) took a hit after former President Donald Trump claimed Coca-Cola uses "too much sugar" and suggested the beverage giant should switch to corn syrup. ADM, a major corn syrup producer, saw its stock dip as investors worried the comments might pressure Coca-Cola to reconsider its sweetener choices—even though there’s no evidence the company plans to change.

Editor’s Note: Trump’s offhand remark might seem like small potatoes, but in the world of big agriculture and Wall Street, even a casual comment can send ripples. ADM’s stock slide shows how reliant commodity-driven companies are on the stability of their key customers—and how quickly uncertainty, even unfounded, can spook investors. For now, it’s more about market nerves than actual policy shifts, but it’s a reminder of how politics and business often collide in unexpected ways.

Investment firm Needham just cut its price target for Jamf—a company that makes Apple device management software—from $22 to $20. The adjustment comes as Jamf shifts its strategy, though the details of that pivot aren’t fully spelled out here. It’s not a huge drop, but it signals some skepticism about how smoothly this transition will go.

Editor’s Note: For investors, even small target cuts like this can hint at bigger questions—like whether Jamf’s new direction will pay off. If you’re holding their stock, it’s worth keeping an eye on how the company explains (and executes) this strategic move in the coming months. Not panic-worthy yet, but definitely a nudge to stay alert.

The UK is facing a significant jobs downturn, with payrolls shrinking by 178,000 over the past year and unemployment hitting a four-year high. Experts like Deutsche Bank’s Sanjay Raja acknowledge the slump but argue the labor market isn’t in freefall—it’s more of a gradual cooling than a crash. Still, the numbers paint a worrying picture for workers and the broader economy.

Editor’s Note: Jobs are getting harder to come by, and that’s bad news for everyone—from workers scrambling for paychecks to businesses bracing for weaker consumer spending. While it’s not a full-blown crisis yet, this slump could ripple through everything from mortgage approvals to holiday spending, making it a story that hits close to home for most Brits.

Abbott Labs posted better-than-expected profits thanks to strong demand for its medical devices, but investors weren’t thrilled—shares dipped after the company’s future earnings forecast fell short of expectations. Basically, they’re doing well now, but Wall Street’s worried about what’s next.

Editor’s Note: Abbott’s story is a classic case of "good news, but..." Their devices (like glucose monitors and heart tech) are selling well, which is great for the business. But the stock drop shows how skittish markets can be—even solid results aren’t enough if the outlook seems shaky. For everyday folks, it’s a reminder that big med-tech companies ride waves of demand (like aging populations needing more care), but they’re not immune to investor nerves.